National Reference Laboratory for Clostridium difficile, Hôpital Saint-Antoine, 34 rue Crozatier, 75012, Paris, France.
Université Paris Descartes, UMR-S1139, Sorbonne Paris Cité, Paris, France.
Health Qual Life Outcomes. 2019 Jan 11;17(1):6. doi: 10.1186/s12955-019-1081-5.
Clostridium difficile infection (CDI) is associated with a substantial Quality of life impact on patients that has not been so far measured with a generic validated instrument.
A prospective study was performed in 7 French acute-care settings in patients presenting with a bacteriologically-confirmed CDI. The EQ-5D-3 L was filled in by patients at 7 ± 2 days after CDI diagnosis to describe their state of health at that date as well as their state of health immediately before the CDI episode (baseline). Individual utility decrement was obtained by subtracting the corresponding utilities. The Quality Adjusted Life Year (QALY) loss was calculated by multiplying the days spent from baseline to the date of the interview, by the decrement of utility. A multivariate analysis of variance of the utility decrement according to CDI and patients characteristics was performed.
Eighty patients were enrolled (mean age: 69.4 years, 55% females). The utility scores dropped from a mean 0.542 (SD: 0.391) at baseline to 0.050 (SD: 0.404) during the CDI episode with a mean adjusted utility decrement of 0.492 (SD: 0.398) point. This decrement increased significantly with CDI severity (Zar score ≥ 3) (p = 0.001), in patients with a positive baseline utility (p = 0.032), in women as compared to men (p = 0.041) and in patients aged more than 65 years (p = 0.041). No association with the Charlson index was found. The associated QALY loss not integrating the excess mortality was 0.028 (SD: 0.053).
The impact on quality of life of CDI episodes is major and translates in a substantial QALY loss despite their short duration.
艰难梭菌感染(CDI)与患者的生活质量受到重大影响相关,但目前尚未使用通用的经过验证的工具进行评估。
在法国 7 家急性医疗机构中开展了一项前瞻性研究,纳入了患有经细菌学证实的 CDI 的患者。患者在 CDI 确诊后 7±2 天填写 EQ-5D-3L,以描述他们在该日期的健康状况以及在 CDI 发作前的健康状况(基线)。通过减去相应的效用值来获得个体效用降低值。通过将从基线到访谈日期的天数乘以效用降低值来计算质量调整生命年(QALY)损失。对 CDI 和患者特征对效用降低值的方差分析进行了多变量分析。
共纳入 80 例患者(平均年龄:69.4 岁,55%为女性)。效用评分从基线时的 0.542(SD:0.391)降至 CDI 发作期间的 0.050(SD:0.404),平均调整后效用降低值为 0.492(SD:0.398)点。该降低值与 CDI 严重程度(Zar 评分≥3)(p=0.001)、基线效用阳性的患者(p=0.032)、女性患者(与男性相比)(p=0.041)和年龄超过 65 岁的患者(p=0.041)显著相关。与 Charlson 指数无关。未纳入超额死亡率的情况下,与 QALY 损失相关的是 0.028(SD:0.053)。
CDI 发作对生活质量的影响是重大的,尽管其持续时间短,但会导致大量 QALY 损失。